Zevin Asset Management LLC Sells 756 Shares of AstraZeneca PLC (NASDAQ:AZN)

Zevin Asset Management LLC trimmed its holdings in shares of AstraZeneca PLC (NASDAQ:AZN) by 0.6% in the third quarter, Holdings Channel.com reports. The firm owned 134,099 shares of the company’s stock after selling 756 shares during the quarter. AstraZeneca makes up 1.6% of Zevin Asset Management LLC’s holdings, making the stock its 27th largest holding. Zevin Asset Management LLC’s holdings in AstraZeneca were worth $10,448,000 as of its most recent SEC filing.

Other institutional investors have also recently bought and sold shares of the company. McClarren Financial Advisors Inc. lifted its position in AstraZeneca by 320.8% during the 3rd quarter. McClarren Financial Advisors Inc. now owns 324 shares of the company’s stock worth $25,000 after buying an additional 247 shares in the last quarter. GHP Investment Advisors Inc. bought a new stake in AstraZeneca during the second quarter worth about $26,000. Capital Performance Advisors LLP acquired a new position in AstraZeneca during the third quarter valued at approximately $28,000. Pathway Financial Advisers LLC acquired a new position in shares of AstraZeneca during the 1st quarter worth approximately $29,000. Finally, CANADA LIFE ASSURANCE Co raised its stake in shares of AstraZeneca by 40.6% during the 1st quarter. CANADA LIFE ASSURANCE Co now owns 506 shares of the company’s stock worth $34,000 after purchasing an additional 146 shares in the last quarter. Institutional investors own 20.35% of the company’s stock.

AstraZeneca Trading Down 2.8 %

Shares of AZN stock opened at $63.23 on Monday. AstraZeneca PLC has a 12-month low of $60.47 and a 12-month high of $87.68. The firm has a 50 day moving average price of $75.03 and a two-hundred day moving average price of $78.23. The company has a quick ratio of 0.71, a current ratio of 0.93 and a debt-to-equity ratio of 0.71. The company has a market capitalization of $196.05 billion, a PE ratio of 30.25, a price-to-earnings-growth ratio of 1.17 and a beta of 0.47.

AstraZeneca (NASDAQ:AZN) last released its quarterly earnings results on Tuesday, November 12th. The company reported $1.04 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.01 by $0.03. The business had revenue of $13.57 billion during the quarter, compared to the consensus estimate of $13.08 billion. AstraZeneca had a return on equity of 30.01% and a net margin of 12.68%. The firm’s quarterly revenue was up 18.0% on a year-over-year basis. During the same period in the previous year, the company posted $0.87 EPS. As a group, analysts predict that AstraZeneca PLC will post 4.07 earnings per share for the current year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently weighed in on the stock. Erste Group Bank upgraded shares of AstraZeneca from a “hold” rating to a “buy” rating in a report on Wednesday, September 11th. TD Cowen upped their target price on shares of AstraZeneca from $90.00 to $95.00 and gave the company a “buy” rating in a report on Monday, August 12th. Finally, Deutsche Bank Aktiengesellschaft upgraded AstraZeneca from a “sell” rating to a “hold” rating in a report on Wednesday, November 6th. Two analysts have rated the stock with a hold rating, seven have given a buy rating and two have issued a strong buy rating to the stock. Based on data from MarketBeat, AstraZeneca currently has an average rating of “Buy” and an average target price of $89.75.

About AstraZeneca

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.